Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 130 entries
View as:

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Phase: N/A Priority: Normal
NCT ID: NCT04243954 Org: User:
Start: 04/10/20 End: 11/21/20 Due: 11/21/21

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06066216 Org: User:
Start: 02/01/24 End: 10/31/26 Due: 10/31/27

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06455072 Org: User:
Start: 02/01/23 End: 01/31/25 Due: 01/31/26

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03788226 Org: User:
Start: 02/01/19 End: 12/31/23 Due: 12/31/24

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05192681 Org: User:
Start: 10/10/21 End: 10/10/23 Due: 10/10/24

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05019690 Org: User:
Start: 10/01/21 End: 06/01/25 Due: 06/01/26

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Phase: N/A Priority: Normal
NCT ID: NCT05649618 Org: User:
Start: 12/05/22 End: 03/31/26 Due: 03/31/27

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05753826 Org: User:
Start: 08/01/23 End: 12/31/27 Due: 12/31/28

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05479240 Org: User:
Start: 09/01/23 End: 06/01/28 Due: 06/01/29

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05799443 Org: User:
Start: 04/05/23 End: 04/05/25 Due: 04/05/26

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Phase: N/A Priority: Normal
NCT ID: NCT05910177 Org: User:
Start: 12/28/23 End: 08/31/26 Due: 08/31/27

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03666221 Org: User:
Start: 11/01/14 End: 11/01/22 Due: 11/01/23

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06463834 Org: User:
Start: 03/20/24 End: 03/19/28 Due: 03/19/29

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06468670 Org: User:
Start: 06/17/24 End: 06/30/27 Due: 06/30/28

HRQOL in Locally Advanced Thyroid Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05824312 Org: User:
Start: 02/01/23 End: 01/31/26 Due: 01/31/27

Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06572293 Org: User:
Start: 11/30/24 End: 12/31/30 Due: 12/31/31

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04955886 Org: User:
Start: 08/31/21 End: 08/31/23 Due: 08/31/24

Cognitive Dysfunction in Patients With Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT03641820 Org: User:
Start: 08/21/18 End: 02/28/19 Due: 02/28/20

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02697838 Org: User:
Start: 08/01/16 End: 10/31/18 Due: 10/31/19

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06208033 Org: User:
Start: 01/10/24 End: 12/30/24 Due: 12/30/25

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05597527 Org: User:
Start: 11/01/22 End: 05/31/25 Due: 05/31/26

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05699655 Org: User:
Start: 05/10/23 End: 04/01/27 Due: 04/01/28

Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03518489 Org: User:
Start: 07/01/18 End: 01/01/19 Due: 01/01/20

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05497076 Org: User:
Start: 09/01/22 End: 07/01/24 Due: 07/01/25

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03380689 Org: User:
Start: 01/05/18 End: 01/05/19 Due: 01/05/20